Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer

ClinicalTrials.gov ID: NCT04489940

Public ClinicalTrials.gov record NCT04489940. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 8:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With HMGA2-expressing Triple Negative Breast Cancer

Study identification

NCT ID
NCT04489940
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Enrollment
11 participants

Conditions and interventions

Interventions

  • Bintrafusp alfa Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 11, 2020
Primary completion
Jan 26, 2022
Completion
Jul 7, 2022
Last update posted
Apr 9, 2023

2020 – 2022

United States locations

U.S. sites
15
U.S. states
10
U.S. cities
15
Facility City State ZIP Site status
Medical Oncology Hematology Consultants, PA, Helen F. Graham Cancer Center, Suite 3400 Newark Delaware 19713-2055
Mayo Clinic-Jacksonville Jacksonville Florida 32224
Maryland Oncology Hematology, P.A. Silver Spring Maryland 20904
New York Oncology Hematology, P.C. - Albany Albany New York 12206
TheOhio State University, Stefanie Spielman Comprehensive Breast Center Columbus Ohio 43212
UPMC Hillman Cancer Center - Hillman Cancer Center Monroeville Pennsylvania 15146
Charleston Hematology Oncology Associates, PA Charleston South Carolina 29414
The West Clinic Germantown Tennessee 38138
Texas Oncology, P.A. - Austin - Austin Central Cancer Center Austin Texas 78731
Texas Oncology, P.A. - Medical City Dallas - Pediatric Hematology/Oncology Dallas Texas 75230
Texas Oncology, P.A. - Plano Plano Texas 75075
Texas Oncology-San Antonio Stone Oak San Antonio Texas 78240
Texas Oncology, P.A. - Tyler Tyler Texas 75702
Virginia Cancer Specialists Fairfax Virginia 22031
Virginia Oncology Associates - Hampton Norfolk Virginia 23502

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 30 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04489940, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 9, 2023 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04489940 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →